Cromolyn sodium prophylaxis inhibits pulmonary proinflammatory cytokines in infants at high risk for bronchopulmonary dysplasia

Rose M. Viscardi, Jeffrey D. Hasday, Karl F. Gumpper, Vicki Taciak, Andrew B. Campbell, Timothy W. Palmer

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

An imbalance of proinflammatory cytokines such as TNF-α IL-1β, and the neutrophil chemotactic factor IL-8 and inhibitors (e.g., soluble TNF receptors and IL-1ra) in the lung during the first week of life may contribute to prolonged pulmonary inflammation and fibrosis in bronchopulmonary dysplasia (BPD). Disodium cromoglycate (DSCG) has anti- inflammatory effects in asthma, a disease with many similarities with BPD. In a prospective, randomized, blinded study, we examined whether early DSCG therapy inhibits proinflammatory cytokines in infants at risk for BPD. Twenty-six infants who were identified as high risk (≤ 75% probability) for oxygen-dependency at 28 d by a 12-h predictive score and survived 48 h were randomized to nebulized DSCG 20 mg (n = 13) or 2 cc NS (control, n = 13) every 6 h from Day 3 to Day 28. Lung lavage was collected on Day 3 (pre- study) and Day 7 and analyzed for cell count and differential and TNF-α, sTNFR1, sTNFR2, IL-1β, IL-1ra, and IL-8 concentrations. The groups' pre- study lavage cytokine concentrations were similar, but TNF-α and IL-8 concentrations were 3.6- and 4.9-fold lower in the DSCG group on Day 7 compared with levels in the control group. Soluble TNF receptors were unaffected by DSCG. There was a trend towards lower IL-1β levels in DSCG- treated infants on Day 7, but IL-1ra levels were unaffected by DSCG therapy. Three control subjects, but no DSCG-treated infants, died during the study period (p = 0.07). There were no significant differences between survivors of the two groups for oxygen-dependency at 28 d (100% control subjects; 85% DSCG). These results suggest that nebulized DSCG may exert an anti- inflammatory effect in the lungs of infants ≤ 1,000 g at risk for BPD.

Original languageEnglish (US)
Pages (from-to)1523-1529
Number of pages7
JournalAmerican journal of respiratory and critical care medicine
Volume156
Issue number5
DOIs
StatePublished - Jan 1 1997

Fingerprint

Bronchopulmonary Dysplasia
Cromolyn Sodium
Cytokines
Lung
Interleukin 1 Receptor Antagonist Protein
Interleukin-8
Interleukin-1
Tumor Necrosis Factor Receptors
Anti-Inflammatory Agents
Oxygen
Pulmonary Fibrosis
Therapeutic Irrigation
Bronchoalveolar Lavage
Pneumonia
Asthma
Cell Count

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Viscardi, Rose M. ; Hasday, Jeffrey D. ; Gumpper, Karl F. ; Taciak, Vicki ; Campbell, Andrew B. ; Palmer, Timothy W. / Cromolyn sodium prophylaxis inhibits pulmonary proinflammatory cytokines in infants at high risk for bronchopulmonary dysplasia. In: American journal of respiratory and critical care medicine. 1997 ; Vol. 156, No. 5. pp. 1523-1529.
@article{d1fb1e26a6bc444a9a53768115161954,
title = "Cromolyn sodium prophylaxis inhibits pulmonary proinflammatory cytokines in infants at high risk for bronchopulmonary dysplasia",
abstract = "An imbalance of proinflammatory cytokines such as TNF-α IL-1β, and the neutrophil chemotactic factor IL-8 and inhibitors (e.g., soluble TNF receptors and IL-1ra) in the lung during the first week of life may contribute to prolonged pulmonary inflammation and fibrosis in bronchopulmonary dysplasia (BPD). Disodium cromoglycate (DSCG) has anti- inflammatory effects in asthma, a disease with many similarities with BPD. In a prospective, randomized, blinded study, we examined whether early DSCG therapy inhibits proinflammatory cytokines in infants at risk for BPD. Twenty-six infants who were identified as high risk (≤ 75{\%} probability) for oxygen-dependency at 28 d by a 12-h predictive score and survived 48 h were randomized to nebulized DSCG 20 mg (n = 13) or 2 cc NS (control, n = 13) every 6 h from Day 3 to Day 28. Lung lavage was collected on Day 3 (pre- study) and Day 7 and analyzed for cell count and differential and TNF-α, sTNFR1, sTNFR2, IL-1β, IL-1ra, and IL-8 concentrations. The groups' pre- study lavage cytokine concentrations were similar, but TNF-α and IL-8 concentrations were 3.6- and 4.9-fold lower in the DSCG group on Day 7 compared with levels in the control group. Soluble TNF receptors were unaffected by DSCG. There was a trend towards lower IL-1β levels in DSCG- treated infants on Day 7, but IL-1ra levels were unaffected by DSCG therapy. Three control subjects, but no DSCG-treated infants, died during the study period (p = 0.07). There were no significant differences between survivors of the two groups for oxygen-dependency at 28 d (100{\%} control subjects; 85{\%} DSCG). These results suggest that nebulized DSCG may exert an anti- inflammatory effect in the lungs of infants ≤ 1,000 g at risk for BPD.",
author = "Viscardi, {Rose M.} and Hasday, {Jeffrey D.} and Gumpper, {Karl F.} and Vicki Taciak and Campbell, {Andrew B.} and Palmer, {Timothy W.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1164/ajrccm.156.5.9611088",
language = "English (US)",
volume = "156",
pages = "1523--1529",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "5",

}

Cromolyn sodium prophylaxis inhibits pulmonary proinflammatory cytokines in infants at high risk for bronchopulmonary dysplasia. / Viscardi, Rose M.; Hasday, Jeffrey D.; Gumpper, Karl F.; Taciak, Vicki; Campbell, Andrew B.; Palmer, Timothy W.

In: American journal of respiratory and critical care medicine, Vol. 156, No. 5, 01.01.1997, p. 1523-1529.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cromolyn sodium prophylaxis inhibits pulmonary proinflammatory cytokines in infants at high risk for bronchopulmonary dysplasia

AU - Viscardi, Rose M.

AU - Hasday, Jeffrey D.

AU - Gumpper, Karl F.

AU - Taciak, Vicki

AU - Campbell, Andrew B.

AU - Palmer, Timothy W.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - An imbalance of proinflammatory cytokines such as TNF-α IL-1β, and the neutrophil chemotactic factor IL-8 and inhibitors (e.g., soluble TNF receptors and IL-1ra) in the lung during the first week of life may contribute to prolonged pulmonary inflammation and fibrosis in bronchopulmonary dysplasia (BPD). Disodium cromoglycate (DSCG) has anti- inflammatory effects in asthma, a disease with many similarities with BPD. In a prospective, randomized, blinded study, we examined whether early DSCG therapy inhibits proinflammatory cytokines in infants at risk for BPD. Twenty-six infants who were identified as high risk (≤ 75% probability) for oxygen-dependency at 28 d by a 12-h predictive score and survived 48 h were randomized to nebulized DSCG 20 mg (n = 13) or 2 cc NS (control, n = 13) every 6 h from Day 3 to Day 28. Lung lavage was collected on Day 3 (pre- study) and Day 7 and analyzed for cell count and differential and TNF-α, sTNFR1, sTNFR2, IL-1β, IL-1ra, and IL-8 concentrations. The groups' pre- study lavage cytokine concentrations were similar, but TNF-α and IL-8 concentrations were 3.6- and 4.9-fold lower in the DSCG group on Day 7 compared with levels in the control group. Soluble TNF receptors were unaffected by DSCG. There was a trend towards lower IL-1β levels in DSCG- treated infants on Day 7, but IL-1ra levels were unaffected by DSCG therapy. Three control subjects, but no DSCG-treated infants, died during the study period (p = 0.07). There were no significant differences between survivors of the two groups for oxygen-dependency at 28 d (100% control subjects; 85% DSCG). These results suggest that nebulized DSCG may exert an anti- inflammatory effect in the lungs of infants ≤ 1,000 g at risk for BPD.

AB - An imbalance of proinflammatory cytokines such as TNF-α IL-1β, and the neutrophil chemotactic factor IL-8 and inhibitors (e.g., soluble TNF receptors and IL-1ra) in the lung during the first week of life may contribute to prolonged pulmonary inflammation and fibrosis in bronchopulmonary dysplasia (BPD). Disodium cromoglycate (DSCG) has anti- inflammatory effects in asthma, a disease with many similarities with BPD. In a prospective, randomized, blinded study, we examined whether early DSCG therapy inhibits proinflammatory cytokines in infants at risk for BPD. Twenty-six infants who were identified as high risk (≤ 75% probability) for oxygen-dependency at 28 d by a 12-h predictive score and survived 48 h were randomized to nebulized DSCG 20 mg (n = 13) or 2 cc NS (control, n = 13) every 6 h from Day 3 to Day 28. Lung lavage was collected on Day 3 (pre- study) and Day 7 and analyzed for cell count and differential and TNF-α, sTNFR1, sTNFR2, IL-1β, IL-1ra, and IL-8 concentrations. The groups' pre- study lavage cytokine concentrations were similar, but TNF-α and IL-8 concentrations were 3.6- and 4.9-fold lower in the DSCG group on Day 7 compared with levels in the control group. Soluble TNF receptors were unaffected by DSCG. There was a trend towards lower IL-1β levels in DSCG- treated infants on Day 7, but IL-1ra levels were unaffected by DSCG therapy. Three control subjects, but no DSCG-treated infants, died during the study period (p = 0.07). There were no significant differences between survivors of the two groups for oxygen-dependency at 28 d (100% control subjects; 85% DSCG). These results suggest that nebulized DSCG may exert an anti- inflammatory effect in the lungs of infants ≤ 1,000 g at risk for BPD.

UR - http://www.scopus.com/inward/record.url?scp=0030659467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030659467&partnerID=8YFLogxK

U2 - 10.1164/ajrccm.156.5.9611088

DO - 10.1164/ajrccm.156.5.9611088

M3 - Article

C2 - 9372670

AN - SCOPUS:0030659467

VL - 156

SP - 1523

EP - 1529

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 5

ER -